Several years ago, a little-known drug named Ozempic — previously used only to treat diabetes — emerged as a promising new ...

The absolute risk for thyroid cancer is low among patients receiving glucagon-like peptide-1 receptor agonist (GLP-1 RA) ...

A new study published in Physiology & Behavior uncovers significant sensory implications of glucagon-like peptide-1 receptor agonists (GLP-1 RAs), medications commonly prescribed for weight loss and ...

The FDA’s approval of Ozempic to battle chronic kidney disease “allows us to more broadly address conditions within cardiovascular-kidney-metabolic syndrome, which affects millions of ...

Cardinal Health had $210 billion in pharmaceutical and specialty drugs sales in fiscal 2024, up 11% year-over-year, helped in large part by GLP-1 sales. In Q4, segment sales rose 13% to $55 billion, ...

For people with diabetes, the use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) is associated with a reduced risk for certain disorders and conditions.

Glucagon-like peptide-1 receptor agonists (GLP-1RAs) such as semaglutide (Wegovy and Ozempic) and tirzepatide (Mounjaro) may ...

Dr. Reddy's Lab is poised to witness crosswinds from a drop in revenue from the patent expiration of Revlimid and increased ...

Sometimes, the conversation doesn’t get past a handful of words, and just the attempt may threaten the patient-physician ...

Galderma, the pure-play dermatology category leader, is pioneering new research into the impact of medication-driven <a target=_ ...

They also don’t directly support behavior change, which Kathryn Ilonka Pollak, PhD, a professor in population health sciences ...

The US Food and Drug Administration on Tuesday approved Ozempic for adults with type 2 diabetes and chronic kidney disease (CKD). The drug is now indicated specifically to treat kidney failure, ...